Khalili, N.; Shooli, H.; Hosseini, N.; Fathi Kazerooni, A.; Familiar, A.; Bagheri, S.; Anderson, H.; Bagley, S.J.; Nabavizadeh, A. Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging. Cancers2023, 15, 5198.
Khalili, N.; Shooli, H.; Hosseini, N.; Fathi Kazerooni, A.; Familiar, A.; Bagheri, S.; Anderson, H.; Bagley, S.J.; Nabavizadeh, A. Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging. Cancers 2023, 15, 5198.
Khalili, N.; Shooli, H.; Hosseini, N.; Fathi Kazerooni, A.; Familiar, A.; Bagheri, S.; Anderson, H.; Bagley, S.J.; Nabavizadeh, A. Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging. Cancers2023, 15, 5198.
Khalili, N.; Shooli, H.; Hosseini, N.; Fathi Kazerooni, A.; Familiar, A.; Bagheri, S.; Anderson, H.; Bagley, S.J.; Nabavizadeh, A. Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging. Cancers 2023, 15, 5198.
Abstract
Clinical management in neuro-oncology has changed to an integrative approach that incorporates molecular profile alongside histopathology and imaging findings. While the WHO guideline recommends genotyping of informative alterations as a routine clinical practice for central nervous system (CNS) tumors, acquisition of tumor tissue in the CNS is invasive and not always possible. Liquid biopsy is a non-invasive approach that provides the opportunity to capture the complex molecular heterogeneity of the whole tumor through detection of circulating tumor biomarkers in body fluids, such as blood or cerebrospinal fluid. Despite all the advantages, the low abundance of tumor-derived biomarkers, particularly in CNS tumors, as well as their short half-life has limited the application of liquid biopsy in clinical practice. Thus, it is crucial to identify factors that are associated with the presence of these biomarkers and explore possible strategies that can increase the shedding of these tumoral components into biological fluids. In this review, we first describe the clinical applications of liquid biopsy in CNS tumors including its roles in early detection of recurrence and monitoring of treatment response. We then discuss the utilization of imaging in identifying factors that affect the detection of circulating biomarkers as well as how image-guided interventions such as focused ultrasound can help enhance the presence of tumor biomarkers through blood-brain barrier disruption.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
*
